Stimulator of interferon genes (STING) agonists rapidly moved into clinical trials with great optimism but have only shown mediocre therapeutic efficacy in patients. Li and colleagues revealed that STING activation in B cells drives immunosuppression that counteracts the stimulatory activity of these drugs, and that blocking regulatory B-cell function can improve STING-based cancer immunotherapy. Using specific deletion of STING (TMEM173) in B cells, they first showed that systemic delivery of STING agonists is more effective in controlling multiple cancer models, most importantly pancreatic ductal adenocarcinomas (PDAC). Next, they found that in response to STING activation, B cells take on a regulatory phenotype and produce two suppressive cytokines, IL35 and IL10. They found that IL35 production is essential for their suppressive nature, acting to suppress natural killer (NK) cell antitumor responses specifically in response to STING agonists. Finally, they showed that a combination of blocking anti-IL35 antibodies in combination...
Skip Nav Destination
Article navigation
1 December 2022
Breaking Insights|
December 02 2022
Highlights from Recent Cancer Literature Available to Purchase
Online ISSN: 1538-7445
Print ISSN: 0008-5472
©2022 American Association for Cancer Research
2022
American Association for Cancer Research
Cancer Res (2022) 82 (23): 4301–4302.
Citation
Highlights from Recent Cancer Literature. Cancer Res 1 December 2022; 82 (23): 4301–4302. https://doi.org/10.1158/0008-5472.CAN-82-23-BI
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Pay-Per-View 24-Hour Access
$50.00
Advertisement
228
Views